Peter S Heeger
Cedars-Sinai Medical Center · Cedars Sinai Medical Center: Transplantation · Icahn School of Medicine at Mount Sinai: Transplantation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Peter S Heeger as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:25 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06919003 · Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)National Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Kidney Transplant · study chair
- Ph2NCT05917522 · Assessment of Biomarker-Guided CNI Substitution In Kidney TransplantationNational Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Kidney Transplant · study chair
- Ph2NCT05518487 · COVID Protection After Transplant - Sanofi GSK (CPAT-SG) StudyNational Institute of Allergy and Infectious Diseases (NIAID) · completed · COVID-19, Kidney Transplant · study chair
- Ph2NCT05077254 · COVID Protection After Transplant-Immunosuppression ReductionNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Kidney Transplant Recipients, Liver Transplant Recipients · study chair
- Ph2NCT02495077 · Effects of Inhibiting Early Inflammation in Kidney Transplant PatientsNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Kidney Transplant · principal investigator
- N/ANCT02255123 · Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 StudyNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Cardiac Transplantation · study chair
- N/ANCT01974999 · A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 StudyNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Kidney Disease, Kidney Failure, End Stage Renal Disease · principal investigator
- Ph2NCT01919346 · Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney TransplantationHeeger, Peter, M.D. · terminated · Delayed Graft Function, Kidney Transplantation, Complement Activity · principal investigator
- Ph2NCT01769443 · Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart TransplantationNational Institute of Allergy and Infectious Diseases (NIAID) · terminated · Primary Heart Transplant, Heart Transplantation, Heart Transplant · principal investigator
- Ph2NCT01517984 · Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney TransplantationNational Institute of Allergy and Infectious Diseases (NIAID) · terminated · Kidney Transplant Recipients · principal investigator
- N/ANCT00466804 · Noninvasive Methods to Monitor Graft Survival in Heart Transplant PatientsNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Heart Transplant · principal investigator
- N/ANCT00308802 · Noninvasive Methods to Monitor Graft Survival in Kidney Transplant PatientsNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Kidney Transplantation · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Assessment of Biomarker Guided CNI Substitution in Kidney TransplantationU01AI170424 · NIAID · CEDARS-SINAI MEDICAL CENTER · fiscal years 2022 to 2026 · $50,000 awarded in 2026Same name and institution; not confirmed by an ID
- Characterization of a LILRB3 SNP cluster in kidney transplant recipients associated with post-transplant renal failureR01DK149129 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2026 · $910,670 awarded in 2026Same name and institution; not confirmed by an ID
- Intra-graft C1 esterase inhibitor therapy for deceased kidney transplantationU01AI184203 · NIAID · CEDARS-SINAI MEDICAL CENTER · fiscal years 2025 to 2026 · $2,216,525 awarded in 2026Same name and institution; not confirmed by an ID
- Intra-graft C1 esterase inhibitor therapy for deceased kidney transplantationR01AI184203 · NIAID · CEDARS-SINAI MEDICAL CENTER · fiscal years 2024 · $2,216,525 awarded in 2024Same name and institution; not confirmed by an ID
- Decay Accelerating Factor and B cell ImmunityR01AI141434 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2019 to 2023 · $423,750 awarded in 2023Same name and institution; not confirmed by an ID
- CTOT: Biomarker guided CNI substitution in kidney transplantationU01AI063594 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2004 to 2022 · $43,166 awarded in 2022Grant number is on one of their registry trials
- Cell Death Pathways and Heart Transplant RejectionR01AI132405 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2017 to 2021 · $550,756 awarded in 2021Same name and institution; not confirmed by an ID
- Translational Immunology Training ProgramT32AI078892 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2008 to 2021 · $379,436 awarded in 2021Same name and institution; not confirmed by an ID
- Decay accelerating factor dependent inhibition of T cell immunityR21AI126009 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2016 to 2017 · $211,875 awarded in 2017Same name and institution; not confirmed by an ID
- Complement & T Cell Medicated Allograft RejectionR01AI071185 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2007 to 2016 · $487,476 awarded in 2016Same name and institution; not confirmed by an ID
- Graft rejection and direct versus indirect recognitionR01AI043578 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 1998 to 2013 · $388,280 awarded in 2013Same name and institution; not confirmed by an ID
- Complement & T Cell Medicated Allograft RejectionR56AI071185 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2012 · $339,000 awarded in 2012Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Expanding HOPE Liver Transplantation: Understanding Opportunistic Infection and Cancer RiskU01AI138897 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Christine Marie Durand, DORRY L. SEGEV, AARON A TOBIAN · fiscal years 2018 to 2026Named on NCT05077254
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:25 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients.J Am Soc Nephrol · 2015175 citationsRCR 6.8
- Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials.Am J Transplant · 202055 citationsRCR 2.8
- Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients: Results of the CTOT-19 Trial.J Am Soc Nephrol · 202327 citationsRCR 2.6
- Heterogeneous alterations in human alloimmunity associated with immunization.Transplantation · 200517 citationsRCR 0.4
- 15 citationsRCR 0.6
- CTOTC-08: A multicenter randomized controlled trial of rituximab induction to reduce antibody development and improve outcomes in pediatric lung transplant recipients.Am J Transplant · 202213 citationsRCR 1.4
- 9 citationsRCR 3.0
- Distinct peripheral blood molecular signature emerges with successful tacrolimus withdrawal in kidney transplant recipients.Am J Transplant · 20207 citationsRCR 0.3
- Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction.Am J Transplant · 20251 citationsRCR 0.5